BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32164620)

  • 1. Mutational landscape differences between young-onset and older-onset breast cancer patients.
    Mealey NE; O'Sullivan DE; Pader J; Ruan Y; Wang E; Quan ML; Brenner DR
    BMC Cancer; 2020 Mar; 20(1):212. PubMed ID: 32164620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors.
    Lopez G; Costanza J; Colleoni M; Fontana L; Ferrero S; Miozzo M; Fusco N
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
    Mathioudaki A; Ljungström V; Melin M; Arendt ML; Nordin J; Karlsson Å; Murén E; Saksena P; Meadows JRS; Marinescu VD; Sjöblom T; Lindblad-Toh K
    Sci Rep; 2020 Nov; 10(1):19304. PubMed ID: 33168853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive molecular portraits of human breast tumours.
    Cancer Genome Atlas Network
    Nature; 2012 Oct; 490(7418):61-70. PubMed ID: 23000897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational signatures among young-onset testicular cancers.
    Mealey NE; O'Sullivan DE; Peters CE; Heng DYC; Brenner DR
    BMC Med Genomics; 2021 Nov; 14(1):280. PubMed ID: 34819066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
    Lopez-Knowles E; Pearson A; Schuster G; Gellert P; Ribas R; Yeo B; Cutts R; Buus R; Garcia-Murillas I; Haynes B; Martin LA; Smith I; Turner N; Dowsett M
    Br J Cancer; 2019 Jan; 120(2):247-255. PubMed ID: 30563991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.
    Krainer M; Silva-Arrieta S; FitzGerald MG; Shimada A; Ishioka C; Kanamaru R; MacDonald DJ; Unsal H; Finkelstein DM; Bowcock A; Isselbacher KJ; Haber DA
    N Engl J Med; 1997 May; 336(20):1416-21. PubMed ID: 9145678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
    Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
    Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
    [No Abstract]   [Full Text] [Related]  

  • 9. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
    Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
    Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics.
    Ding YC; Song H; Adamson AW; Schmolze D; Hu D; Huntsman S; Steele L; Patrick CS; Tao S; Hernandez N; Adams CD; Fejerman L; Gardner K; Nápoles AM; Pérez-Stable EJ; Weitzel JN; Bengtsson H; Huang FW; Neuhausen SL; Ziv E
    Cancer Res; 2023 Aug; 83(15):2600-2613. PubMed ID: 37145128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis.
    Encinas G; Maistro S; Pasini FS; Katayama ML; Brentani MM; Bock GH; Folgueira MA
    Rev Assoc Med Bras (1992); 2015; 61(5):474-83. PubMed ID: 26603012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genetic landscape of breast carcinomas with neuroendocrine differentiation.
    Marchiò C; Geyer FC; Ng CK; Piscuoglio S; De Filippo MR; Cupo M; Schultheis AM; Lim RS; Burke KA; Guerini-Rocco E; Papotti M; Norton L; Sapino A; Weigelt B; Reis-Filho JS
    J Pathol; 2017 Feb; 241(3):405-419. PubMed ID: 27925203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Juvenile papillomatosis of the breast (Swiss cheese disease) has frequent associations with PIK3CA and/or AKT1 mutations.
    Guillet C; Rechsteiner M; Bellini E; Choschzick M; Moskovszky L; Dedes K; Papassotiropoulos B; Varga Z
    Hum Pathol; 2020 Apr; 98():64-73. PubMed ID: 32088208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
    Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors.
    Arnold JM; Choong DY; Thompson ER; ; Waddell N; Lindeman GJ; Visvader JE; Campbell IG; Chenevix-Trench G
    Breast Cancer Res Treat; 2010 Jan; 119(2):491-6. PubMed ID: 19189213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
    Verhoog LC; van den Ouweland AM; Berns E; van Veghel-Plandsoen MM; van Staveren IL; Wagner A; Bartels CC; Tilanus-Linthorst MM; Devilee P; Seynaeve C; Halley DJ; Niermeijer MF; Klijn JG; Meijers-Heijboer H
    Eur J Cancer; 2001 Nov; 37(16):2082-90. PubMed ID: 11597388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
    BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
    Luen SJ; Viale G; Nik-Zainal S; Savas P; Kammler R; Dell'Orto P; Biasi O; Degasperi A; Brown LC; Láng I; MacGrogan G; Tondini C; Bellet M; Villa F; Bernardo A; Ciruelos E; Karlsson P; Neven P; Climent M; Müller B; Jochum W; Bonnefoi H; Martino S; Davidson NE; Geyer C; Chia SK; Ingle JN; Coleman R; Solbach C; Thürlimann B; Colleoni M; Coates AS; Goldhirsch A; Fleming GF; Francis PA; Speed TP; Regan MM; Loi S
    Ann Oncol; 2023 Apr; 34(4):397-409. PubMed ID: 36709040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
    Frank TS; Deffenbaugh AM; Hulick M; Gumpper K
    Dis Markers; 1999 Oct; 15(1-3):89-92. PubMed ID: 10595259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.